ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2309

Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis

Cynthia K. Manos1,2, Rui Xiao3, Timothy G. Brandon1, Alexis Ogdie4 and Pamela F. Weiss5,6, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, 3Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, 4Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 6Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Comorbidity, Pediatric rheumatology, psoriasis, psoriatic arthritis and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis.  It is also unknown whether children with PsA are at increased risk of cardiovascular and metabolic disease, similar to adults. 

Methods: We conducted a retrospective cohort study of children with incident psoriasis and PsA using the Clinformatics TM DataMart (OptumInsight, Eden Prairie, MD), a de-identified administrative claims database.  All incident psoriasis patients had ≥1 ICD-9 code for psoriasis and PsA patients had ≥ 1 ICD-9 code for PsA or psoriasis and arthritis.  The index date was the date of the first ICD-9 code for the diagnosis of psoriasis or PsA.  Patients were required to be continuously enrolled for 6 months before and 12 months after the index date.  Controls were matched on age, sex, and date of psoriasis or arthritis diagnosis at a 10:1 ratio.  Cox proportional hazard regression was performed to assess the risk of developing arthritis in children with psoriasis over time.  Incidence rate ratios were used to compare the relative frequency of cardiovascular and metabolic co-morbid diagnoses.

Results: We identified 1,012 children with PsA, 14,610 with psoriasis, and 203,907 controls.  The median time of continuous enrollment was 3.0 years (IQR 1.9-4.9).  Median ages at the first diagnoses of PsA and psoriasis were 12 and 10 years, respectively.  56% and 53% of children with PsA and psoriasis were female.  Amongst those children who had both psoriasis and arthritis, approximately 37% developed psoriasis first.  Median time to development of arthritis after psoriasis diagnosis was 1.8 years (IQR 0.4-2.8).  Older age was associated with a significantly increased risk of developing arthritis in children with psoriasis (Table 1). There was a trend towards increased risk of arthritis in psoriasis patients with ulcerative colitis and uveitis, albeit statistically insignificant.  Children with psoriatic arthritis had a significantly increased incidence of hypertension, hyperlipidemia, and cerebrovascular disease compared to healthy controls (Table 2). 

Conclusion: Older age was a risk factor for PsA among children with psoriasis.  Similar to adults, PsA was associated with a higher risk of developing metabolic and cerebrovascular disease in children.

 


Disclosure: C. K. Manos, None; R. Xiao, None; T. G. Brandon, None; A. Ogdie, Pfizer, 2,AbbVie, Celgene and Pfizer, 2,Novartis, Takeda and Pfizer, 5; P. F. Weiss, None.

To cite this abstract in AMA style:

Manos CK, Xiao R, Brandon TG, Ogdie A, Weiss PF. Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-arthritis-and-the-development-of-comorbid-cardiovascular-and-metabolic-disease-in-children-with-psoriasis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-arthritis-and-the-development-of-comorbid-cardiovascular-and-metabolic-disease-in-children-with-psoriasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology